June 7, 2022 07:15 AM EDT

FDA slams small pharma for misleading ad with a dearth of safety info and dubious stat calculations

Zachary Brennan

Senior Editor

The FDA’s Office of Prescription Drug Promotion slapped its 3rd untitled letter of the year onto New Jersey-based Althera Pharmaceuticals earlier this month, with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA slams small pharma for misleading ad with a dearth of safety info and dubious stat calculations

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

FDA slams small phar­ma for mis­lead­ing ad with a dearth of safe­ty in­fo and du­bi­ous stat cal­cu­la­tions

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA slams small pharma for misleading ad with a dearth of safety info and dubious stat calculations